Objectives. To examine the feasibility of using milrinone to test pulmonary vascular reactivity in patients before heart transplantation, we tested the hypothesis that milrinone would lower pulmonary vascular resistance (PVR) in patients with severe heart failure.
Pulmonary vascular resistance (PVR) is frequently elevated in patients with chronic heart failure, despite conventional medical therapy (1, 2) . Because fixed pulmonary hypertension is a risk factor for right heart failure and death after heart transplantation (1, (3) (4) (5) , preoperative pharmacologic assessment of the reversibility of pulmonary vascular hypertension has become a requisite part of the pretransplantation evaluation. The ability to lower PVR to Յ200 dynes-s-cm Ϫ5 without systemic hypotension with nitroprusside, the agent most commonly used to assess pulmonary vascular reactivity before transplantation, indicates a favorable short-term prognosis (6) . However, nitroprusside requires careful dose titration, and in many patients its use is limited by hypotension due to systemic vasodilation (6) . Other agents that have been used to assess pulmonary vasoreactivity before transplantation include prostaglandin E 1 (7) , adenosine (8) and inhaled nitric oxide (9 -12) .
Milrinone is an intravenously active phosphodiesterase inhibitor that exerts both positive inotropic and direct vasodilator effects (13, 14) . In patients with severe heart failure, we previously found (15) that milrinone increased cardiac output (CO) and reduced systemic vascular resistance (SVR) to a greater extent than nitroprusside when the agents were given at rates that caused matched reductions in arterial blood pressure. This observation suggests that if milrinone is an effective pulmonary vasodilator, it may be associated with a smaller decrease in systemic arterial pressure, for a given decrease in PVR, relative to nitroprusside. However, despite the clinical use of milrinone for several years, there is almost no information available regarding its effect on PVR. The purpose of the present study was to determine whether milrinone can be used to test for reversibility of pulmonary vascular hypertension in patients with heart failure. To examine this possibility, we tested the hypothesis that milrinone would lower PVR if administered as a rapid intravenous bolus in patients with severe heart failure undergoing evaluation for heart transplantation.
Methods
Study patients. The study included 27 patients (20 men, 7 women; mean [ϮSEM] age 52 Ϯ 2 years, range 36 to 74) with chronic New York Heart Association functional class III (n ϭ 23) or IV (n ϭ 4) heart failure and a PVR Ն200 dynes-s-cm Ϫ5 who were referred for consideration for heart transplantation (n ϭ 26) or for management of heart failure (n ϭ 1). The underlying etiology of heart failure was idiopathic dilated cardiomyopathy in 12 patients, ischemic cardiomyopathy in 12, rheumatic heart disease in 1, adriamycin toxicity in 1 and hypertrophic cardiomyopathy in 1. The majority of patients were receiving digoxin (85%), diuretic drugs (96%), an angiotensin-converting enzyme inhibitor (93%) and Coumadin (85%). Other cardiac medications included amiodarone (19%), hydralazine (7%), nitrates (26%) and beta-adrenergic antagonists (11%). Left ventricular ejection fraction and enddiastolic dimension by echocardiography were 0.22 Ϯ 0.02 (range 0.10 to 0.48) and 70 Ϯ 3 mm (range 50 to 100), respectively. Written informed consent was obtained from all patients.
Hemodynamic measurements. Digoxin and diuretic and vasodilator drugs were withheld for at least 12 h before catheterization. No premedication other than local anesthesia (1% lidocaine) was used. Right heart catheterization was performed through the right internal jugular vein or right femoral vein using a 7F Swan-Ganz catheter (Arrow International, Inc.). Systemic arterial pressure was monitored from a radial artery cannula or through a 6F sidearm sheath placed in the right femoral artery (Cordis Laboratories). The electrocardiogram, systemic arterial, right atrial (RA), pulmonary artery (PA) and pulmonary artery wedge (PAW) pressures were recorded on a strip-chart recorder (Electronics for Medicine, PPG Biomedical Systems Division). The designation PAW pressure, as used herein, refers to a PA occluded pressure, as is typically obtained by inflation of the Swan-Ganz catheter balloon in a distal PA branch. The PA and PAW pressures were meaned electronically; CO was determined by the Fick method using the measured oxygen consumption (model MRM 2B, Waters Instruments, Inc.) and oxygen content in the PA and systemic arteries. Oxygen content was calculated from blood hemoglobin and oxygen saturation by standard methods. Blood oxygen saturation was determined in duplicate samples (Ciba-Corning model 270 Co-oximeter). Derived hemodynamic variables were calculated using standard formulas as follows: Cardiac index (liters/min per m 2 ) ϭ CO/Body surface area; Transpulmonary pressure gradient (mm Hg) ϭ Mean PA pressure Ϫ PAW pressure; SVR (dynes-s-cm Study protocol. With the patient supine and breathing room air, baseline hemodynamic data were obtained as the mean of two sets of measurements separated by at least 10 min and differing by Ͻ10%. Milrinone was administered through a systemic vein as an intravenous bolus of 50 g/kg body weight over a period of 1 min. Hemodynamic measurements were repeated every 5 min for a total of 20 min.
Statistical methods. Results are presented as mean value Ϯ SEM. The hemodynamic effects of milrinone over time were analyzed by two-way analysis of variance using a term for patient identification and post hoc analysis with the Student Newman-Keuls test. The SAS statistical package (SAS Institute) was used for these analyses. Differences between subgroups were determined by two-tailed unpaired t tests. Least squares linear regression analysis was used to determine the relation between various hemodynamic variables and the magnitude of the PVR response to milrinone. Differences were considered significant if the null hypothesis could be rejected at the 0.05 probability level.
Results
Baseline hemodynamic variables. Rest hemodynamic variables (Table 1 ) revealed moderate to severe heart failure with elevated right and left heart filling pressures, a reduced CO and elevated SVR. Significant pulmonary hypertension was present, with elevated PA pressures, a mean transpulmonary pressure gradient of 15 Ϯ 1 mm Hg and a mean PVR of 356 Ϯ 26 dynes-s-cm
Ϫ5
. Hemodynamic response to milrinone. The hemodynamic effects of a single rapid bolus infusion of milrinone were maximal at 5 to 10 min after the infusion and persisted for at least 20 min (Table 1 , Fig. 1 to 4) . Milrinone decreased the systolic, diastolic and mean PA pressures (9%, 14% and 12%, respectively, at 5 min) (Fig. 1) . Mean PAW pressure decreased (16 Ϯ 5% at 5 min) in parallel with the decrease in mean PA pressure. Consequently, the transpulmonary gradient was unchanged ( Fig. 1) . The CO increased by 42 Ϯ 4% at 5 min (Fig.  2) . The PVR decreased in parallel with the increase in CO, with a peak effect at 5 to 10 min (Fig. 3) . The PVR decreased in all but one patient by 5 min (mean decrease 31 Ϯ 4%) (Fig.
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CO ϭ cardiac output NO ϭ nitric oxide PA ϭ pulmonary artery PAW ϭ pulmonary artery wedge PVR ϭ pulmonary vascular resistance RA ϭ right atrial SVR ϭ systemic vascular resistance 4) and fell below 200 dynes-s-cm Ϫ5 in 63 Ϯ 9% of the patients at some time between 5 and 20 min after the infusion. The one patient in whom PVR increased at 5 min (from 269 to 296 dynes-s-cm
Ϫ5
) subsequently had a maximal PVR reduction of 43% at 15 min. Milrinone decreased SVR by 30 Ϯ 3% at 5 min but had no effect on systolic arterial pressure, RA pressure or heart rate.
Determinants of PVR response to milrinone. The magnitude of the decrease in PVR with milrinone did not correlate with the baseline mean PA pressure, mean PAW pressure, CO or PVR (data not shown). The magnitude of change in PVR with milrinone also did not correlate with the magnitude of the milrinone-induced decreases in mean PA or PAW pressure (r ϭ 0.29 and r ϭ 0.06, respectively). However, the decrease in PVR correlated inversely with the increase in CO (r ϭ Ϫ0.48, p ϭ 0.01) (Fig. 5) .
To examine further whether the PVR-lowering effect of milrinone was related to baseline hemodynamic variables or other hemodynamic effects of milrinone, patients with a milrinone-induced PVR reduction above and below the median (43%) were compared. Milrinone decreased PVR Ն43% (mean 55 Ϯ 2%) in 14 patients and Ͻ43% (mean 25 Ϯ 2%) in 13 patients (Table 2 ). The two groups did not differ with regard to baseline PVR or its determinants (mean PA and mean PAW pressures, CO, transpulmonary pressure gradient), although the PAW pressure tended to be higher in the more responsive group. The milrinone-induced changes in mean PA and mean PAW pressures were similar in the two groups. However, the more responsive group had a larger milrinone-induced increase in CO (56 Ϯ 5% vs. 40 Ϯ 6%, p ϭ 0.04) and decrease in transpulmonary gradient (34 Ϯ 4% vs. 0 Ϯ 5%, p Ͻ 0.001).
Discussion
The major new finding of this study is that milrinone decreases the PVR in patients with pulmonary vascular hyper- *p Ͻ 0.01 versus baseline. Data presented are mean value Ϯ SEM. CI ϭ cardiac index; CO ϭ cardiac output; DAP ϭ diastolic arterial pressure; HR ϭ heart rate; MAP ϭ mean arterial pressure; PAD ϭ pulmonary artery diastolic pressure; PAM ϭ pulmonary artery mean pressure; PAS ϭ pulmonary artery systolic pressure; PAWP ϭ pulmonary artery wedge pressure; PVR ϭ pulmonary vascular resistance; RAP ϭ right atrial pressure; SAP ϭ systolic arterial pressure; SVR ϭ systemic vascular resistance; TPG ϭ transpulmonary gradient. tension secondary to left ventricular failure. The systemic hemodynamic effects of milrinone have been well characterized in patients with left ventricular failure. Intravenous infusion of milrinone in such patients increases CO and stroke volume while decreasing left and right heart filling pressures and SVR (15) (16) (17) . Although a decrease in PA pressure has been noted with milrinone, the effect of milrinone on PVR has not been studied in detail.
Effect of milrinone on hemodynamic variables and PVR. We found that the rapid infusion of milrinone as a bolus over 1 min decreased PVR in all patients studied, with a mean decrease of 31 Ϯ 4% at 5 min. The decrease in PVR occurred rapidly, with a maximal effect in 5 to 10 min and was sustained for at least 20 min. Milrinone also decreased SVR, but systemic arterial pressure was unchanged because of the increase in CO. Milrinone caused parallel decreases in PA and PAW pressures and increased CO. Milrinone did not decrease the transpulmonary pressure gradient, and therefore the decrease in PVR was due entirely to the increase in CO. Likewise, the decrease in PVR correlated with the milrinoneinduced increase in CO but not with changes in PA, PAW or transpulmonary pressures. Because the transpulmonary gradient did not increase in the setting of a higher CO, by definition, the resistance to pulmonary blood flow (i.e., PVR) decreased.
Mechanism. The mechanism responsible for the milrinoneinduced decrease in PVR is not known. Milrinone is a phosphodiesterase inhibitor that appears to act primarily by increasing the levels of cyclic adenosine monophosphate in myocardial and vascular tissues (18, 19) . In vivo and in vitro studies have shown (14, 20) that milrinone exerts a direct relaxant effect on vascular smooth muscle. Thus, milrinone may have lowered PVR as a result of a direct relaxant effect on the pulmonary vasculature (21, 22) . However, the pulmonary hemodynamic effects of milrinone differ from those of two other potent direct-acting vasodilators-nitroprusside and nitric oxide (NO)-in patients with heart failure. Nitroprusside decreases PVR because of both a decrease in transpulmonary pressure gradient and an increase in CO (23, 24) . We (9) and others (10, 11) have found that inhaled NO has no effect on CO or mean PA pressure but decreases the transpulmonary pressure gradient due to an increase in PAW pressure. We propose that this increase in PAW pressure reflects increased left ventricular venous return due to the decrease in PVR and is therefore evident in patients with left ventricular failure but not those with normal left ventricular function.
These observations suggest that milrinone may lower PVR, Data presented are mean value Ϯ SEM. Abbreviations as in Table 1. at least in part, by a mechanism other than direct pulmonary vasodilation. In patients with heart failure, milrinone causes both direct vasodilation and a positive inotropic effect (13, 14) , and it has been shown (13, 15) that both effects contribute to the increase in CO. It is well known that the pulmonary vasculature has the ability to accommodate rapid increases in blood flow without an increase in the transpulmonary pressure gradient through the recruitment of parallel vessels (25) . In addition, it is now apparent that an increase in blood flow can induce vasodilation in several vascular beds, including the pulmonary vasculature (26, 27) , by the release of endothelial cell NO (28 -30) . Thus, it is possible that the milrinoneinduced decrease in PVR is due, at least in part, to the increase in CO, which results in a secondary decrease in PVR by recruitment of accessory vessels or flow-mediated vasodilation, or both. Coddens et al. (31) have also suggested that the pulmonary vasodilator effects of nitroprusside and dobutamine may be secondary to increased pulmonary blood flow. Pulmonary vascular resistance testing before heart transplantation. Preoperative assessment of pulmonary vascular reactivity is routinely performed to identify patients with fixed pulmonary hypertension who are at increased risk for right heart failure and death after orthotopic heart transplantation (32, 33) . Nitroprusside is the agent most commonly used for this purpose. The response to nitroprusside has been used to stratify patients into high and low risk groups for postoperative complications (4, 6) . A limitation to the use of nitroprusside is that the systolic arterial pressure falls below 85 mm Hg in ϳ27% of patients and may thereby preclude full assessment of pulmonary vascular reactivity (6) . Several other pharmacologic agents have been used to test pulmonary vasoreactivity before transplantation. Prostaglandin E 1 has been shown (7) to decrease the transpulmonary pressure gradient and PVR to a greater degree than nitroprusside, but like nitroprusside, prostaglandin E 1 lowered mean arterial pressure to a substantial degree. As discussed earlier, inhaled NO effectively lowers PVR in patients with heart failure but does so at the expense of increasing the left heart filling pressure (9, 10, 12) . Adenosine caused a greater decrease in transpulmonary pressure gradient than nitroprusside without lowering systemic arterial pressure, but like NO, was limited by its tendency to increase the PAW pressure (8) .
This study demonstrates that milrinone can be used to rapidly assess pulmonary vascular reactivity during evaluation for heart transplantation. In this regard, it is noteworthy that milrinone did not decrease systemic arterial pressure and was well tolerated, even by patients with a low arterial pressure. This observation is consistent with previous studies (15) (16) (17) 34 ) that have shown little or no decrease in arterial pressure with intravenous milrinone. We previously demonstrated that, compared with nitroprusside in the same patients, milrinone caused a greater increase in CO for any given decrease in SVR or arterial pressure (15) , apparently due to the fact that milrinone increases CO due to both direct vasodilator and positive inotropic actions (13) . Other attractive features of the bolus administration of milrinone for the pretransplantation evaluation of pulmonary vascular reactivity are the simplicity and rapidity of the test. Whether milrinone has advantages over other agents used for this purpose, such as nitroprusside or inhaled NO, remains to be determined. In addition, because the number of patients studied was small and they were not followed up after transplantation, no conclusions can be drawn regarding the predictive value of the milrinone response for posttransplantation events.
Conclusions. We showed that a single rapid bolus infusion of milrinone effectively lowers PVR in patients with left ventricular failure and is well tolerated. This effect may be due to a direct pulmonary vasodilator effect of the drug or to a secondary effect due to the increase in CO, or both. These data suggest that milrinone may be a useful agent for testing pulmonary vascular reactivity in patients being evaluated for heart transplantation.
